Healthcare
PolyPid Ltd.(PYPD)
Live Price
Offline$4.62
+1.09% today
1Y Change
+25.54%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $50.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +57.4%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PolyPid Ltd. (PYPD) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $4.62 and up 25.5% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +57.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +57.4%, free cash flow +100.0% with operating margin 0.0% and ROIC -95.2%. Stock Foundry combines PYPD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 13, 2026 with an EPS surprise of +25.5%.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +57.4%, while operating margin sits near 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 12, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | +25.5% | +3.8% | +14.9% | +8.3% |
2026 Feb 11, 2026 | -20.6% | -0.6% | -7.6% | -9.7% |
2025 Nov 12, 2025 | +31.5% | -4.5% | -4.0% | +6.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PYPD
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PYPD Max Drawdown
-17.11%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PYPD and SPY.
Company Overview
PolyPid Ltd.
NASDAQ Global Market
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
- Leadership
- Dikla Czaczkes Akselbrad
- IPO Date
- Jun 26, 2020
- Employees
- 57
- Street Address
- 18 Hasivim Street
- Mailing
- Petah Tikva, 4959376
- Region
- Petah Tikva, IL
- Reporting Currency
- USD
- Investor Line
- 972 7 4719 5700
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 8.3
Growth
- Revenue
- 0.0%
- EPS
- +57.4%
- Free Cash Flow
- +100.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -291.4%
- ROIC
- -95.2%
Balance Sheet
- Debt/Equity
- 0.25
- Current Ratio
- 1.97
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.